Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ metabolism
Carbapenems
/ pharmacology
Cross-Sectional Studies
Disk Diffusion Antimicrobial Tests
Drug Resistance, Multiple, Bacterial
Ethiopia
/ epidemiology
Fermentation
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Prevalence
Prospective Studies
beta-Lactamases
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
01
2019
accepted:
10
09
2019
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
12
3
2020
Statut:
epublish
Résumé
The emergence of multidrug-resistance (MDR), production of extended-spectrum β-lactamases, and carbapenemase in members of fermentative gram-negative bacilli are a serious threat to public health. The aim of this study was to determine the burden of multi-drug resistance, the production of extended-spectrum β-lactamases (ESBLs), and carbapenemase in fermentative Gram-negative bacilli in Ethiopian Public Health Institute. A cross-sectional study was carried out from December 2017 to June 2018. Different clinical samples were collected, inoculated, and incubated according to standard protocols related to each sample. Bacterial identification was performed by using the VITEKR 2 compact system using the GNR card. Antimicrobial susceptibility testing was carried out by the Kirby-Bauer disc diffusion method. Production of ESBL and carbapenemase were confirmed by combination disc and modified Hodge Test method respectively. A total of 238 fermentative Gram-negative bacilli were recovered during the study period, among which E.coli were the predominant isolates followed by K. pneumoniae. The highest percentage of antibiotic resistance was noted against ampicillin (100%) followed by trimethoprim/sulfamethoxazole (81.9%). The isolates showed better sensitivity towards carbapenem drugs. Out of 238 isolates, 94.5% were MDR and of which 8.8% and 0.8% were extensively and pan drug resistant, respectively. Nearly 67% and 2% of isolates were producers of ESBL and carbapenemase, respectively. The isolation rates of MDR, ESBL, and carbapenemase producing stains of the isolates were ≥70% in intensive care unit while the isolation rates in other wards were ≤25%. The findings of this study revealed that the burden of MDR and ESBL was high and carbapenemase producing isolates were also identified which is concerning. This situation warrants a consistent surveillance of antimicrobial resistance of fermentative Gram-negative bacilli and implementation of an efficient infection control program.
Sections du résumé
BACKGROUND
The emergence of multidrug-resistance (MDR), production of extended-spectrum β-lactamases, and carbapenemase in members of fermentative gram-negative bacilli are a serious threat to public health.
OBJECTIVE
The aim of this study was to determine the burden of multi-drug resistance, the production of extended-spectrum β-lactamases (ESBLs), and carbapenemase in fermentative Gram-negative bacilli in Ethiopian Public Health Institute.
MATERIALS AND METHODS
A cross-sectional study was carried out from December 2017 to June 2018. Different clinical samples were collected, inoculated, and incubated according to standard protocols related to each sample. Bacterial identification was performed by using the VITEKR 2 compact system using the GNR card. Antimicrobial susceptibility testing was carried out by the Kirby-Bauer disc diffusion method. Production of ESBL and carbapenemase were confirmed by combination disc and modified Hodge Test method respectively.
RESULTS
A total of 238 fermentative Gram-negative bacilli were recovered during the study period, among which E.coli were the predominant isolates followed by K. pneumoniae. The highest percentage of antibiotic resistance was noted against ampicillin (100%) followed by trimethoprim/sulfamethoxazole (81.9%). The isolates showed better sensitivity towards carbapenem drugs. Out of 238 isolates, 94.5% were MDR and of which 8.8% and 0.8% were extensively and pan drug resistant, respectively. Nearly 67% and 2% of isolates were producers of ESBL and carbapenemase, respectively. The isolation rates of MDR, ESBL, and carbapenemase producing stains of the isolates were ≥70% in intensive care unit while the isolation rates in other wards were ≤25%.
CONCLUSIONS
The findings of this study revealed that the burden of MDR and ESBL was high and carbapenemase producing isolates were also identified which is concerning. This situation warrants a consistent surveillance of antimicrobial resistance of fermentative Gram-negative bacilli and implementation of an efficient infection control program.
Identifiants
pubmed: 31553773
doi: 10.1371/journal.pone.0222911
pii: PONE-D-19-02621
pmc: PMC6760794
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Carbapenems
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0222911Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Antimicrob Agents. 2013 Oct;42(4):372-4
pubmed: 23978353
Int J Antimicrob Agents. 2005 Jan;25(1):1-10
pubmed: 15620820
Jpn J Infect Dis. 2005 Aug;58(4):228-31
pubmed: 16116256
Antimicrob Resist Infect Control. 2015 Apr 17;4:12
pubmed: 25908966
Ethiop J Health Sci. 2012 Jul;22(2):121-8
pubmed: 22876076
Clin Infect Dis. 2006 Mar 1;42(5):692-9
pubmed: 16447117
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S11-23
pubmed: 12516026
Infect Drug Resist. 2017 Jan 25;10:27-34
pubmed: 28182124
Indian J Med Microbiol. 2011 Apr-Jun;29(2):91-2
pubmed: 21654100
Am J Infect Control. 2006 Jun;34(5 Suppl 1):S20-8; discussion S64-73
pubmed: 16813978
Cleve Clin J Med. 2013 Apr;80(4):225-33
pubmed: 23547093
New Microbes New Infect. 2015 Feb 12;8:166-70
pubmed: 27257498
Am J Trop Med Hyg. 2013 Nov;89(5):960-964
pubmed: 24043693
Afr Health Sci. 2011 Aug;11 Suppl 1:S40-5
pubmed: 22135643
BMC Res Notes. 2010 Dec 24;3:348
pubmed: 21184671
BMC Pharmacol Toxicol. 2015 Jun 02;16:14
pubmed: 26031914
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
BMC Infect Dis. 2016 Jul 11;16:326
pubmed: 27400864
Can J Infect Dis Med Microbiol. 2018 Dec 13;2018:4846159
pubmed: 30651898
Crit Care. 2011;15(2):215
pubmed: 21457501
BMC Res Notes. 2014 Aug 07;7:500
pubmed: 25100042
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Clin Infect Dis. 2009 Sep 1;49(5):682-90
pubmed: 19622043
Antimicrob Resist Infect Control. 2019 Feb 15;8:39
pubmed: 30815254
Emerg Infect Dis. 2011 Jan;17(1):143-4
pubmed: 21192883
Nature. 2013 Mar 14;495(7440):141
pubmed: 23495392
Indian J Crit Care Med. 2014 Oct;18(10):643-5
pubmed: 25316972
Niger Postgrad Med J. 2015 Oct-Dec;22(4):223-7
pubmed: 26776335
Int J Antimicrob Agents. 2012 Sep;40(3):282-4
pubmed: 22817914
Pan Afr Med J. 2014 Oct 21;19:177
pubmed: 25815098
Ther Clin Risk Manag. 2016 Feb 18;12:251-60
pubmed: 26937197
Emerg Infect Dis. 2002 Jan;8(1):63-8
pubmed: 11749750
Biomed Res Int. 2014;2014:303104
pubmed: 24707481
J Nat Sci Biol Med. 2014 Jan;5(1):30-5
pubmed: 24678193
PLoS One. 2019 Apr 15;14(4):e0215177
pubmed: 30986262
Antimicrob Resist Infect Control. 2015 Oct 26;4:42
pubmed: 26504518